Mechanism of potentiation of tissue-type plasminogen activator

被引:0
|
作者
Lazos, SA [1 ]
Wong, SS [1 ]
机构
[1] UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL & LAB MED,HOUSTON,TX 77030
来源
关键词
tissue-type plasminogen activator; fibrinogen; plasminogen; fibrin; fibrin fragments; synthetic peptide;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The conversion of plasminogen to plasmin catalyzed by tissue-type plasminogen activator is accelerated in the presence of fibrin, leading to an increased dissolution of fibrin clots. This rate enhancement is mimicked by a dodecapeptide segment of the fibrin molecule containing the sequence A alpha 149-160 (RLEVDIDIKIRS). At low concentrations of the dodecapeptide, the potentiation increases with concentration, but at high concentrations, the stimulation effect diminishes, giving rise to a bell-shaped curve. The maximum rate enhancement of about 10 fold is achieved at a concentration of 85 mu g/mL. This concentration dependent phenomenon is also observed for two synthetic peptide analogues, GLEVDIDIKIRS and RGGGGGGGKIRS, although the acceleration potential is less. These results indicate that the N-terminal amino acids are not critical for the rate enhancement. The bell-shaped activity-concentration curve suggests that the dodecapeptide may bind to both plasminogen and t-PA. This speculation is further supported by the modification of the potentiator. When the A alpha 149-160 dodecapeptide is pretreated with trypsin or phenyl glyoxal, the potentiation activity is eliminated. We speculate that the acceleration of the plasminogen-to-plasmin reaction catalyzed by t-PA is achieved through the action of the stimulator to bring the enzyme and its substrate together as a bi-dentate cross-linker. This effect increases the apparent concentration of the substrate at the enzyme active site, and is reflected as a decrease in Michaelis-Menten constant.
引用
收藏
页码:1071 / 1077
页数:7
相关论文
共 50 条
  • [1] Tissue-type plasminogen activator
    Pittman, GL
    ARCHIVES OF NEUROLOGY, 1998, 55 (10) : 1377 - 1377
  • [2] TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    MCDONALD, C
    SHUMAN, M
    BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1985, 366 (09): : 823 - 824
  • [3] Human tissue-type plasminogen activator
    Kruithof, Egbert K. O.
    Dunoyer-Geindre, Sylvie
    THROMBOSIS AND HAEMOSTASIS, 2014, 112 (02) : 243 - 254
  • [4] The Tissue-Type Plasminogen Activator Story
    Collen, D.
    Lijnen, H. R.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (08) : 1151 - 1155
  • [5] TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    LIJNEN, HR
    COLLEN, D
    ANNALES DE BIOLOGIE CLINIQUE, 1987, 45 (02) : 198 - 201
  • [6] Is tissue-type plasminogen activator a neuromodulator?
    Fernández-Monreal, M
    López-Atalaya, JP
    Benchenane, K
    Léveillé, F
    Cacquevel, M
    Plawinski, L
    MacKenzie, ET
    Bu, GJ
    Buisson, A
    Vivien, D
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2004, 25 (04) : 594 - 601
  • [7] TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    TURAZZA, FM
    POGNA, M
    MEDICINA-RIVISTA DELLA ENCICLOPEDIA MEDICA ITALIANA, 1990, 10 (01): : 75 - 78
  • [8] Converting tissue-type plasminogen activator into a zymogen
    Tachias, K
    Madison, EL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (46) : 28749 - 28752
  • [9] Tissue-type plasminogen activator—harmful or beneficial?
    Denis Vivien
    Carine Ali
    Nature Reviews Neurology, 2012, 8 : 538 - 539
  • [10] Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury
    Reddrop, C
    Moldrich, RX
    Beart, PM
    Farso, M
    Liberatore, GT
    Howells, DW
    Petersen, KU
    Schleuning, WD
    Medcalf, RL
    STROKE, 2005, 36 (06) : 1241 - 1246